Title
Category
Credits
Event date
Cost
  • CMHC
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with heart failure. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), and despite a higher HF symptom burden, they are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps. In recent years, significant advances in the prevention and treatment of HF have been made, all with the potential to alter treatment paradigms now and in the future.
  • CMHC
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Atrial fibrillation (AF) remains underdiagnosed, particularly in African American patients with a high burden of AF risk factors, such as those with cardiometabolic comorbidities. Additionally, stroke prevention in these patients is suboptimal, with suboptimal application of evidence-based therapies and guidelines, including the suboptimal use of direct oral anticoagulants (DOACs).
  • CMHC
  • 2.00 ABIM MOC and AMA PRA Category 1 Credit
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit
  • 2.00 ANCC
  • 2.00 CDE
  • 2.00 Participation
$0.00
Non-alcoholic steatohepatitis (NASH) is a metabolic-based constellation of multiple organ pathology that overlaps with obesity, prediabetes, type 2 diabetes, and cardiovascular disease. The sequelae of NASH, stemming from nonalcoholic fatty liver disease (NAFLD), has at the root of it, several of these cardiometabolic risk factors and existing cardiovascular disease.
  • CMHC
  • 1.25 ABIM MOC and AMA PRA Category 1 Credit
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
$0.00
Anemia is a common comorbidity in patients with chronic kidney disease (CKD), and is associated with significant morbidity and impacts on quality of life. The complicated pathophysiology of the condition and the disadvantages associated with current treatments are some of the major barriers that clinicians face in reducing the burden of anemia in patients with CKD.
  • CMHC
  • 1.25 ABIM MOC and AMA PRA Category 1 Credit
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
$0.00
Lowering LDL-C effectively and safely is crucial to prevent and lower the risk of adverse cardiovascular events, however, LDL-C goal achievement remains suboptimal, including in high-risk and very high-risk patients. The landscape of LDL-C lowering therapy has significantly evolved, with new consensus statements, newer agents, as well as important evidence that may help address some of the current gaps. Additionally, there is residual risk beyond LDL-C, including elevated triglyceride levels and elevated Lp(a).
  • CMHC
  • 19.25 ACPE Pharmacy
  • 19.25 AMA PRA Category 1 Credit
  • 19.25 ANCC
  • 19.25 CDE
  • 19.25 Participation
$0.00
The recordings from the 18th Annual meeting are now available. 
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
This activity consists of a recorded presentation at the 18th annual CMHC Annual Congress held from October 18-21, 2023, in Boston, MA. The session, “Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults: Perspectives & Advances,” was presented by Keith C. Ferdinand, MD, and Debbie Cohen, MD. Drs. Ferdinand and Cohen discussed:The strategies to overcome barriers to hypertension control and cardiovascular diseases.The definitions, current treatment, and emerging approaches for resistant hypertension.